The association of mobilising regimen on immune reconstitution and survival in myeloma patients treated with bortezomib, cyclophosphamide and dexamethasone induction followed by a melphalan autograft.

Antineoplastic Combined Chemotherapy Protocols / therapeutic use Autografts Bortezomib / therapeutic use Cyclophosphamide / therapeutic use Dexamethasone / therapeutic use Granulocyte Colony-Stimulating Factor / therapeutic use Hematopoietic Stem Cell Mobilization Humans Immune Reconstitution Melphalan / therapeutic use Multiple Myeloma / drug therapy Retrospective Studies

Journal

Bone marrow transplantation

ISSN: 1476-5365

Titre abrégé: Bone Marrow Transplant

Pays: England

ID NLM: 8702459

Informations de publication

Date de publication:
09 2021

Historique:

received: 10 02 2021

accepted: 08 04 2021

revised: 24 03 2021

pubmed: 30 4 2021

medline: 14 10 2021

entrez: 29 4 2021

Statut: ppublish

Résumé

G-CSF only mobilisation has been shown to enhance immune reconstitution early post-transplant, but its impact on survival remains uncertain. We undertook a retrospective review of 12 transplant centres to examine overall survival (OS) and time to next treatment (TTNT) following melphalan autograft according to mobilisation method (G-CSF only vs. G-CSF and cyclophosphamide [CY]) in myeloma patients uniformly treated with bortezomib, cyclophosphamide and dexamethasone induction. Six centres had a policy to use G-CSF alone and six to use G-CSF + CY. Patients failing G-CSF only mobilisation were excluded. 601 patients were included: 328: G-CSF + CY, 273: G-CSF only. Mobilisation arms were comparable in terms of age, Revised International Staging System (R-ISS) groups and post-transplant maintenance therapy. G-CSF + CY mobilisation generated higher median CD34 + yields (8.6 vs. 5.5 × 10

Identifiants

DOI: 10.1038/s41409-021-01300-2 PMID: 33911199

pubmed: 33911199

doi: 10.1038/s41409-021-01300-2

pii: 10.1038/s41409-021-01300-2

doi:

Substances chimiques

Granulocyte Colony-Stimulating Factor 143011-72-7

Bortezomib 69G8BD63PP

Dexamethasone 7S5I7G3JQL

Cyclophosphamide 8N3DW7272P

Melphalan Q41OR9510P

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

2152-2159

Informations de copyright

Références

Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M, et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol. 2005;23:9227–33.

pubmed: 16275936 doi: 10.1200/JCO.2005.03.0551

Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014;371:895–905.

pubmed: 25184862 doi: 10.1056/NEJMoa1402888

Gay F, Oliva S, Petrucci MT, Conticello C, Catalano L, Corradini P, et al. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncol. 2015;16:1617–29.

pubmed: 26596670 doi: 10.1016/S1470-2045(15)00389-7

Gertz MA, Kumar SK, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, et al. Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma. Bone Marrow Transpl. 2009;43:619–25.

doi: 10.1038/bmt.2008.369

Varmavuo V, Mantymaa P, Silvennoinen R, Nousiainen T, Kuittinen T, Jantunen E. CD34+ cell subclasses and lymphocyte subsets in blood grafts collected after various mobilization methods in myeloma patients. Transfusion. 2013;53:1024–32.

pubmed: 22897584 doi: 10.1111/j.1537-2995.2012.03848.x

Valtola J, Silvennoinen R, Ropponen A, Siitonen T, Saily M, Sankelo M, et al. Blood graft cellular composition and posttransplant outcomes in myeloma patients mobilized with or without low-dose cyclophosphamide: a randomized comparison. Transfusion. 2016;56:1394–401.

pubmed: 27041692 doi: 10.1111/trf.13574

Uy GL, Costa LJ, Hari PN, Zhang MJ, Huang JX, Anderson KC, et al. Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation. Bone Marrow Transpl. 2015;50:1513–8.

doi: 10.1038/bmt.2015.190

Silvennoinen R, Anttila P, Saily M, Lundan T, Heiskanen J, Siitonen TM, et al. A randomized phase II study of stem cell mobilization with cyclophosphamide+G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma. Bone Marrow Transpl. 2016;51:372–6.

doi: 10.1038/bmt.2015.236

Lin TL, Wang PN, Kuo MC, Hung YH, Chang H, Tang TC. Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma. J Clin Apher. 2016;31:423–8.

pubmed: 26340986 doi: 10.1002/jca.21421

Tuchman SA, Bacon WA, Huang LW, Long G, Rizzieri D, Horwitz M, et al. Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma. J Clin Apher. 2015;30:176–82.

pubmed: 25293363 doi: 10.1002/jca.21360

Tanimura A, Hirai R, Nakamura M, Takeshita M, Hagiwara S, Miwa A. Improved progression-free and event-free survival in myeloma patients undergoing PBSCH receiving a cyclophosphamide + G-CSF regimen than G-CSF alone. Int J Hematol. 2018;107:559–67.

pubmed: 29388164 doi: 10.1007/s12185-018-2408-4

Dingli D, Nowakowski GS, Dispenzieri A, Lacy MQ, Hayman S, Litzow MR, et al. Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma. Clin Lymphoma Myeloma. 2006;6:384–8.

pubmed: 16640814 doi: 10.3816/CLM.2006.n.014

Czerw T, Sadus-Wojciechowska M, Michalak K, Najda J, Mendrek W, Sobczyk-Kruszelnicka M, et al. Increased efficacy of stem cell chemomobilization with intermediate-dose cytarabine plus granulocyte colony-stimulating factor (G-CSF) compared with G-CSF alone in patients with multiple myeloma: results of a randomized trial. Biol Blood Marrow Transpl. 2018;25:248–55.

Desikan KR, Barlogie B, Jagannath S, Vesole DH, Siegel D, Fassas A, et al. Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. J Clin Oncol. 1998;16:1547–53.

pubmed: 9552064 doi: 10.1200/JCO.1998.16.4.1547

Alegre A, Tomas JF, Martinez-Chamorro C, Gil-Fernandez JJ, Fernandez-Villalta MJ, Arranz R, et al. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone. Bone Marrow Transpl. 1997;20:211–7.

doi: 10.1038/sj.bmt.1700867

Costa LJ, Miller AN, Alexander ET, Hogan KR, Shabbir M, Schaub C, et al. Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization. Bone Marrow Transpl. 2011;46:523–8.

doi: 10.1038/bmt.2010.170

Mohty M, Hubel K, Kroger N, Aljurf M, Apperley J, Basak GW, et al. Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation. Bone Marrow Transpl. 2014;49:865–72.

doi: 10.1038/bmt.2014.39

Duong HK, Savani BN, Copelan E, Devine S, Costa LJ, Wingard JR, et al. Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transpl. 2014;20:1262–73.

doi: 10.1016/j.bbmt.2014.05.003

Popat U, Saliba R, Thandi R, Hosing C, Qazilbash M, Anderlini P, et al. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transpl. 2009;15:718–23.

doi: 10.1016/j.bbmt.2009.02.011

Chua CC, Lim HY, Chai KL, Ong J, Sim S, Wood C, et al. Peripheral blood stem cell mobilisation with G-CSF alone versus G-CSF and cyclophosphamide after bortezomib, cyclophosphamide and dexamethasone induction in multiple myeloma. Bone Marrow Transpl. 2018;53:1116–23.

doi: 10.1038/s41409-018-0152-2

Hiwase DK, Hiwase S, Bailey M, Bollard G, Schwarer AP. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transpl. 2008;14:116–24.

doi: 10.1016/j.bbmt.2007.08.051

Skerget M, Skopec B, Zontar D, Cernelc P. Mobilization with cyclophosphamide reduces the number of lymphocyte subpopulations in the leukapheresis product and delays their reconstitution after autologous hematopoietic stem cell transplantation in patients with multiple myeloma. Radiol Oncol. 2016;50:402–8.

pubmed: 27904448 pmcid: 5120577 doi: 10.1515/raon-2016-0028

Kim H, Sohn HJ, Kim S, Lee JS, Kim WK, Suh C. Early lymphocyte recovery predicts longer survival after autologous peripheral blood stem cell transplantation in multiple myeloma. Bone Marrow Transpl. 2006;37:1037–42.

doi: 10.1038/sj.bmt.1705373

Porrata LF. Autograft immune effector cells and survival in autologous peripheral blood hematopoietic stem cell transplantation. J Clin Apher. 2018;33:324–30.

pubmed: 29232011 doi: 10.1002/jca.21611

Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–e46.

pubmed: 27511158 doi: 10.1016/S1470-2045(16)30206-6

Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: A report from international myeloma working group. J Clin Oncol. 2015;33:2863–9.

pubmed: 26240224 pmcid: 4846284 doi: 10.1200/JCO.2015.61.2267

Pusic I, Jiang SY, Landua S, Uy GL, Rettig MP, Cashen AF, et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transpl. 2008;14:1045–56.

doi: 10.1016/j.bbmt.2008.07.004

Chao NJ, Grima DT, Carrum G, Holmberg L, Fung HC, Brown S, et al. Chemo-mobilization provides superior mobilization and collection in autologous stem cell transplants but with less predictability and at a higher cost. Blood 2011;118:4048.

doi: 10.1182/blood.V118.21.4048.4048

Giralt S, Costa L, Schriber J, Dipersio J, Maziarz R, McCarty J, et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transpl. 2014;20:295–308.

doi: 10.1016/j.bbmt.2013.10.013

Desikan KR, Tricot G, Munshi NC, Anaissie E, Spoon D, Fassas A, et al. Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone. Br J Haematol. 2001;112:242–7.

pubmed: 11167811 doi: 10.1046/j.1365-2141.2001.02498.x

Bensinger W, Appelbaum F, Rowley S, Storb R, Sanders J, Lilleby K, et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol. 1995;13:2547–55.

pubmed: 7595706 doi: 10.1200/JCO.1995.13.10.2547

Roberts C, Sabo R, Shickle L. Cost-effective stem cell mobilization: a novel early plerixafor salvage strategy is optimally resource-effective compared to chemotherapy, G-CSF or initial plerixafor strategies [abstract no. O378]. Bone Marrow Transpl. 2011;46:S60–S1.

Turk JL, Poulter LW. Selective depletion of lymphoid tissue by cyclophosphamide. Clin Exp Immunol. 1972;10:285–96.

pubmed: 5046868 pmcid: 1713172

Al-Homsi AS, Roy TS, Cole K, Feng Y, Duffner U. Post-transplant high-dose cyclophosphamide for the prevention of graft-versus-host disease. Biol Blood Marrow Transpl. 2015;21:604–11.

doi: 10.1016/j.bbmt.2014.08.014

Porrata LF, Litzow MR, Inwards DJ, Gastineau DA, Moore SB, Pineda AA, et al. Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin’s lymphoma. Bone Marrow Transpl. 2004;33:291–8.

doi: 10.1038/sj.bmt.1704355

Porrata LF, Gertz MA, Inwards DJ, Litzow MR, Lacy MQ, Tefferi A, et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood. 2001;98:579–85.

pubmed: 11468153 doi: 10.1182/blood.V98.3.579

Schmidmaier R, Oversohl N, Schnabel B, Straka C, Emmerich B. Helper T cells (CD3+/CD4+) within the autologous peripheral blood stem cell graft positively correlate with event free survival of multiple myeloma patients. Exp Oncol. 2008;30:240–3.

pubmed: 18806749

Porrata LF, Burgstaler EA, Winters JL, Jacob EK, Gastineau DA, Suman VJ, et al. Immunologic autograft engineering and survival in non-Hodgkin lymphoma. Biol Blood Marrow Transpl. 2016;22:1017–23.

doi: 10.1016/j.bbmt.2016.01.024

Rueff J, Medinger M, Heim D, Passweg J, Stern M. Lymphocyte subset recovery and outcome after autologous hematopoietic stem cell transplantation for plasma cell myeloma. Biol Blood Marrow Transpl. 2014;20:896–9.

doi: 10.1016/j.bbmt.2014.03.007

Quach H, Ritchie D, Stewart AK, Neeson P, Harrison S, Smyth MJ, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2010;24:22–32.

pubmed: 19907437 doi: 10.1038/leu.2009.236

Kansagra A, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Hogan WJ, et al. Infusion of autograft natural killer cell/CD14(+)HLA-DR(DIM) cell ratio predicts survival in lymphoma post autologous stem cell transplantation. Bone Marrow Transpl. 2018;53:146–54.

doi: 10.1038/bmt.2017.225

Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Hogan WJ, et al. Infused autograft lymphocyte-to-monocyte ratio and survival in T-cell lymphoma post-autologous peripheral blood hematopoietic stem cell transplantation. J Hematol Oncol. 2015;8:80.

pubmed: 26138828 pmcid: 4490710 doi: 10.1186/s13045-015-0178-5

Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Hogan WJ, et al. Infused autograft lymphocyte to monocyte ratio and survival in diffuse large B cell lymphoma. Biol Blood Marrow Transpl. 2014;20:1804–12.

doi: 10.1016/j.bbmt.2014.07.012

Ansell K, Porrata L. Autograft monocytes: the bad humors of autologous peripheral blood hematopoietic stem cell transplantation. J Stem Cell Res Ther. 2013;3:1.

Luyckx A, Schouppe E, Rutgeerts O, Lenaerts C, Fevery S, Devos T, et al. G-CSF stem cell mobilization in human donors induces polymorphonuclear and mononuclear myeloid-derived suppressor cells. Clin Immunol. 2012;143:83–7.

pubmed: 22341087 doi: 10.1016/j.clim.2012.01.011